公司介绍

Genuine Biotech is an innovation- and R&D-driven biotech company dedicated to the development, manufacturing and commercialization of novel drugs for the treatment of viral infections, oncological and cardio-cerebrovascular diseases. The company’s mission is to improve human health through genuine innovation, with a particular focus on the antiviral and anti-tumor fields, and to explore and address drug resistance in existing treatment options. The company aims to find new and better treatment options to address unmet medical needs.

Leveraging the advanced technology platform and strong R&D capabilities, the company has built a broad and competitive product pipeline, especially in the field of antiviral and anti-tumor drugs. The Core Product, azvudine, a Class 1.1 innovative drug, was conditionally approved by the NMPA for the treatment of HIV infection and COVID-19 in July 2021 and July 2022, respectively. Azvudine was the first NMPA-approved oral antiviral treatment for COVID-19 developed by a Chinese company, demonstrating outstanding efficacy in treating viral infections. With its unique dual target mechanism of action, azvudine has become the world's first HIV infection treatment option for the dual-targeted inhibition of nucleoside reverse transcriptase and the Vif inhibitor. The company is also continuously expanding its applications into new indications and combination treatment.